Biotech Stock News (NLNK) (TTPH)

NewLink Genetics (NASDAQ:NLNK) On Monday May 9, 2016 in after-hours trade share of NewLink Genetics tanked by 35% after the company had announced the failure of its phase 3 trial in treating patients with pancreatic cancer. Th phase 3 trial was known as the IMPRESS trial. This phase 3 trial had recruited a total of … Read more